NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 26 to 50 of 12046

Display Results as:

Support of NIGMS Program Project Grants (P01) - PAR-11-220

Organization: NIGMS 

Posting Date: 05-31-2011 

Expiration Date: 07-19-2013 

Activity Code: P01 

Summary: This funding opportunity announcement (FOA) issued by the National Institute of General Medical Sciences encourages innovative, interactive program project grant applications from institutions/organizations that propose to conduct research which aims to solve a significant biological problem, important for the mission of NIGMS, through a collaborative approach involving outstanding scientists who might not otherwise collaborate. The program project grant mechanism is designed to support research in which the funding of several interdependent projects as a group offers significant scientific advantages over support of these same projects as individual regular research grants.  

The Development Of Frontal Cortex And Limbic System And Their Roles In Drug Abuse (R01) - PA-11-027

Organization: NIDA 

Posting Date: 11-10-2010 

Expiration Date: 12-12-2013 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) issued by NIDA encourages Research Project Grant (R01) applications from institutions/organizations that propose to study the development of the frontal and prefrontal cortices, together with the subcortical areas of the limbic system, that play significant roles in mediating emotional and motivated behavior. This initiative is designed to support the basic neuroscience research into the fundamental mechanisms of development of the frontal and prefrontal cortices, as well as the midbrain and basal forebrain structures that mediate a number of functions related to drug abuse and psychiatric disorders including: the euphoric properties of drugs, actions of psychotherapeutic agents, and memory, cognitive and emotional functions. An additional major goal of this initiative is to understand how exposure to drugs of abuse affects the cellular and molecular mechanisms underlying nervous system development of circuits implicated in drug reward and addiction.  

The Market for Long-Term Care Insurance (R01) - RFA-RM-11-002

Organization: Roadmap 

Posting Date: 11-12-2010 

Expiration Date: 01-19-2011 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) solicits research (R01) applications from institutions/organizations proposing to advance knowledge on the economics of long-term care (LTC), including topics related to private and public LTC insurance, the Community Living Assistance Services and Supports (CLASS) program, and related topics. The FOA is a component of the Common Fund initiative on Health Economics for Health Care Reform (http://nihroadmap.nih.gov/healtheconomics).  

Translational Research to Help Older Adults Maintain their Health and Independence in the Community (R21) - PA-11-124

Organization: NIA 

Posting Date: 02-16-2011 

Expiration Date: 03-21-2014 

Activity Code: R21 

Summary: The National Institute on Aging (NIA) and the Administration on Aging (AoA) invite applications using the (R21)award mechanism for translational research that moves evidence-based research findings towards the development of new interventions, programs, policies, practices, and tools that can be used by community-based organizations to help elderly individuals remain healthy and independent, and living in their own homes and communities. The goal of this FOA is to support translational research involving collaborations between academic research centers and community-based organizations with expertise serving the elderly (such as city and state health departments, city/town leadership councils, and Area Agencies on Aging) that will enhance our understanding of practical tools, techniques, programs and policies that communities across the nation can use to more effectively respond to needs of their aging populations.  

Translational Tools for Clinical Studies of Mind/Body and Manual Therapy CAM Interventions (R01) - RFA-AT-11-003

Organization: NCCIH  (formerly NCCAM)

Posting Date: 11-16-2010 

Expiration Date: 04-30-2011 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) issued by the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to develop, enhance, and validate translational tools to facilitate rigorous study of complementary/alternative medicine (CAM) approaches that are in wide use by the public. Data from the most recent National Health Interview Survey [http://www.cdc.gov/nchs/nhis.htm] establish that Americans are utilizing CAM approaches to promote health and well-being, to treat or prevent disease, and for symptom relief. CAM approaches being widely used include manual therapies, meditation, and yoga with chronic pain, back pain and musculoskeletal pain being the most commonly cited reasons for their use. This FOA focuses on encouraging the development of improved research methodology to study safety, efficacy, and clinical effectiveness of mind-body interventions (such as meditation), manual therapies (such as spinal manipulation or massage), and/or yoga therapy. Investigations of other CAM interventions (including natural products, dietary supplements, acupuncture or traditional Chinese medicine) are not allowed for this FOA.  

Understanding and Treating Co-Morbid Conditions in Adolescents with Intellectual and Developmental Disabilities (R21) - PA-11-041

Organization: NICHD 

Posting Date: 11-17-2010 

Expiration Date: 01-08-2014 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grant (R01, R03, R21) applications from institutions/organizations that propose to focus investigator initiated research upon the factors that impact functioning and quality of life in individuals with intellectual and developmental disabilities (IDD) during adolescence.  

"FAILURE TO THRIVE" SYNDROME AMONG OLDER PERSONS - PA-93-022

Organization: NIA 

Posting Date: 11-20-1992 

Expiration Date: 11-20-1995 

Activity Code: K01 K07 K08 K11 

Summary: Recently, a geriatric syndrome termed "failure to thrive" has been described, consisting of weight loss, decreased appetite, poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low serum cholesterol. Failure to thrive occurs in both acute and chronic forms, leading to impaired functional status, morbidity from infection, pressure sores, and increased mortality. This syndrome has been identified as an aging research priority in the Institute of Medicine"s report: Extending Life, Enhancing Life. A National Research Agenda on Aging. (Institute of Medicine, National Academy Press, Washington, 1991.) The relationships between nutritional, metabolic and other pathophysiologic factors in failure to thrive and their effects on clinical outcomes remain to be clarified. While there is evidence that psychiatric conditions (major and subsyndromal depression and cognitive decline) are frequently associated with failure to thrive, the nature of this association needs to be clarified.  

(Re)Building a Kidney Coordinating Center (U01) - RFA-DK-14-009

Organization: NIDDK 

Posting Date: 09-02-2014 

Expiration Date: 01-15-2015 

Activity Code: U01 

Summary: This Funding Opportunity Announcement (FOA) is a new initiative to invite applications to participate in the Kidney Consortium as the Coordinating Center. The consortium Coordinating Center will manage activities of the consortium including research opportunities (e.g., the Opportunity Pool program), and facilitate communication of research results, data, and methods within the consortium and with the community. 

(Re)Building a Kidney: Cells to Organ (UH2/UH3) - RFA-DK-14-010

Organization: NIDDK 

Posting Date: 09-02-2014 

Expiration Date: 01-15-2015 

Activity Code: UH2/UH3 

Summary: This Funding Opportunity Announcement (FOA) invites new research project applications to participate in the NIDDK (Re)Building a Kidney Consortium. The projects will be part of a research network focused on the expansion of tools, resources, and knowledge that will guide studies on the in vivo regeneration of functional nephrons or in vitro generation of nephrons for kidney transplant. Funds will be made available through the UH2/UH3 cooperative agreement award mechanism. The initial UH2 phase will support milestone-driven projects that will inform strategies for the enhancement of endogenous regenerative repair processes and generation of cell types important for the development of functional nephrons. UH2 projects that have met their scientific milestones will be eligible for transition to the second UH3 phase after NIH administrative review. The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. UH3 phase will support milestone-driven projects. It is anticipated that relevant projects will be integrated as appropriate to further synergistic interactions and collaborations.  

1000 Genomes Project Data Processing (U01) - RFA-HG-09-001

Organization: NHGRI 

Posting Date: 11-04-2008 

Expiration Date: 01-13-2009 

Activity Code: U01 

Summary: Purpose. The international 1000 Genomes Project is designed to produce a new high-resolution resource on human genetic variation to support genome-wide association studies and other studies of human disease and biology. This FOA solicits proposals to continue to develop, evaluate, and implement the methods needed to monitor data quality, to produce a basic set of derived data types from the sequence data, to integrate those data, and to develop new tools for additional data analysis to produce the final Project dataset. Projects funded under this FOA will be expected to participate in the highly collaborative international consortium that is carrying out the 1000 Genomes Project. Mechanism of Support. This FOA will utilize the U01 cooperative agreement grant mechanism. Funds Available and Anticipated Number of Awards. The total amount of funding that the NHGRI expects to award through this announcement is up to $3 million for each of two years. It is anticipated that about 4-6 awards will be made.  

1000 Genomes Project Dataset Analysis (U01) - RFA-HG-09-002

Organization: NHGRI 

Posting Date: 11-04-2008 

Expiration Date: 06-27-2009 

Activity Code: U01 

Summary: Purpose. The international 1000 Genomes Project is designed to produce a new high-resolution resource on human genetic variation to support genome-wide association studies and other studies of human disease and biology. The primary source of data will be light sequencing of the genomes of about 1200-1500 anonymized individuals. These data should be sufficient to find most DNA sequence variants in the human population that have a frequency of 1% or more. Several large-scale sequencing centers, including three funded by NHGRI, are involved in this international effort. Currently pilot projects are underway to assess the sequencing platforms and provide data that will be used to design the full-scale project. By the end of 2008 the full-scale project should be underway; it is expected to take about two years and produce about 20 Terabases of sequence data. The Project regularly will release raw sequence data and data derived from the sequence data, such as genotype calls for single-nucleotide polymorphisms (SNPs) and structural variants, and their linkage disequilibrium patterns. This FOA solicits proposals to characterize and analyze the full dataset, such as for allele frequency distribution and signals of natural selection, to produce additional data types, to evaluate the strategies used to develop the dataset, and to develop the tools needed to work with the data and apply them to other studies such as genome-wide association studies.  

2007 NIH Director's New Innovator Award Program (DP2) - RFA-RM-07-009

Organization: Roadmap 

Posting Date: 03-09-2007 

Expiration Date: 05-23-2007 

Activity Code: DP2 

Summary: -Purpose. The NIH Director’s New Innovator Award (http://grants.nih.gov/grants/new_investigators/innovator_award/), created this year, addresses two important goals: stimulating highly innovative research and supporting promising new investigators. New investigators may have exceptionally innovative research ideas, but not the required preliminary data to fare well in the traditional peer review system. As part of its commitment to increasing the success of new investigators, NIH has created the NIH Director’s New Innovator Award to support exceptionally creative new investigators who propose highly innovative approaches that have the potential to produce an unusually high impact. The New Innovator Award program complements the more traditional R01 mechanism, which continues to be the primary source of funding for new investigators. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the DP2 grant mechanism. Applications proposing multiple PIs are not allowed. -Funds Available and Anticipated Number of Awards. Total funding available for this five-year program is at least $40 million for the five-year period. It is anticipated that at least 14 awards will be made. 

2007 NIH Director's Pioneer Award Program (DP1) - RFA-RM-07-005

Organization: Roadmap 

Posting Date: 10-11-2006 

Expiration Date: 01-17-2007 

Activity Code: DP1 

Summary: -Purpose. The National Institutes of Health (NIH) is engaged in a series of initiatives, collectively known as the “NIH Roadmap for Medical Research” (http://nihroadmap.nih.gov), which promote clinical and translational investigation and aim to improve health and prevent disease. The NIH Director’s Pioneer Award Program, is a High-Risk Research initiative of Research Teams of the Future. The term “pioneering” is used to describe highly innovative approaches that have the potential to produce an unusually high impact, and the term “award” is used to mean a grant for conducting research, rather than a reward for past achievements. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the DP1 grant mechanism. -Funds Available and Anticipated Number of Awards. Approximately five to ten awards of $500,000 in direct costs are anticipated for a total of up to $5 million per year for five years.  

2008 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1) - RFA-DA-08-003

Organization: NIDA 

Posting Date: 11-09-2007 

Expiration Date: 03-27-2008 

Activity Code: DP1 

Summary: -Purpose. This program is intended to fund scientists engaged in basic, clinical, or translational research on drug abuse and HIV/AIDS.The term avant-garde is used to describe highly innovative approaches that have the potential to produce an unusually high impact.The proposed research should reflect ideas substantially different from those already being pursued by the investigator or others. The research proposed must be in an area described in the Trans NIH Plan for HIV-Related Research (http://www.oar.nih.gov/updates/updates.htm) and be drug abuse relevant but need not be in a conventional biomedical or behavioral discipline. -Mechanism of Support. This FOA will utilize the NIH DP1 grant mechanism. -Funds Available and Anticipated Number of Awards. Approximately 2 to 3 awards of $500,000 in direct costs are anticipated for a total of up to $2 million per year for five years.  

2008 NIH Director's Pioneer Award Program (DP1) - RFA-RM-08-013

Organization: Roadmap 

Posting Date: 11-01-2007 

Expiration Date: 01-17-2008 

Activity Code: DP1 

Summary: The NIH Director’s Pioneer Award Program is meant to complement NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transformative approaches to major contemporary challenges that have the potential to produce a major impact in a broad area of biomedical or behavioral research. To be considered pioneering, the proposed research must reflect ideas substantially different from those already being pursued in the investigator’s laboratory or elsewhere. Purpose. The National Institutes of Health (NIH) is engaged in a series of initiatives, collectively known as the “NIH Roadmap for Medical Research” (http://nihroadmap.nih.gov) to help enable the agency to sustain its historic record of making cutting-edge contributions to biomedical and behavioral sciences. The NIH Director’s Pioneer Award Program, is a High-Risk Research initiative of Research Teams of the Future. The term “pioneering” is used to describe highly innovative approaches that have the potential to produce an unusually high impact in a broad area of biomedical and behavioral research, and the term “award” is used to mean a grant for conducting research, rather than a reward for past achievements. Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the DP1 grant mechanism. Funds Available and Anticipated Number of Awards. Total funding available is approximately $5 million for the five-year period. It is anticipated that at least 5-10 awards will be made in 2008.  Budget and Project Period. Awards will be for $500,000 in direct costs each year for five years. Standard F&A costs will be determined at the time of award. Eligible Institutions/Organizations. The following domestic (U.S.) institutions are eligible to apply: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.) Non-domestic (non U.S.) entities (Foreign Organizations) are not eligible to apply. Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals who meet the eligibility criteria and who possess the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Women and members of groups underrepresented in biomedical or behavioral research are especially encouraged to apply. Investigators at all career levels who are currently engaged in research are eligible to apply. The research proposed need not be in a conventional biomedical or behavioral discipline; if the applicant’s experience is in non-biological areas, however, he/she must demonstrate a commitment to exploring topics of biomedical or behavioral relevance. If selected, applicants must show evidence of institutional infrastructure support. Awardees are required to commit the major portion (at least 51%) of their research effort to activities supported by the Pioneer Award. Applicants who were not selected for an award in prior years may submit applications this year. There are no citizenship or residency requirements. Number of Applications. Applicants may submit only one application as a PD/PI in response to this FOA. There is no limit to the number of applications that institutions may submit. Renewals and Resubmissions: Renewal (formerly “competing continuation”) applications are not allowed. Resubmission (formerly revision or amended) applications are not to be submitted. All Pioneer Award applications will be considered “new” applications, regardless of any previous applications to the Program 

2008 NIH Director’s New Innovator Award Program (DP2) - RFA-RM-08-014

Organization: Roadmap 

Posting Date: 11-09-2007 

Expiration Date: 04-01-2008 

Activity Code: DP2 

Summary: -Purpose. The NIH Director’s New Innovator Award (http://grants.nih.gov/grants/new_investigators/innovator_award/) was created in 2007 to support a small number of new investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The research proposed need not be in a conventional biomedical or behavioral discipline but must be relevant to the mission of NIH. The New Innovator Awards complement ongoing efforts by NIH and its institutes and centers to fund new investigators through R01 grants, which continue to be the major sources of NIH support for new investigators. Thirty New Innovator Awards were made in 2007. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the DP2 grant mechanism -Funds Available and Anticipated Number of Awards. Total funding available is approximately $55 million for the five-year period. It is anticipated that up to 24 awards will be made in 2008.  

2009 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1) - RFA-DA-09-011

Organization: NIDA 

Posting Date: 12-12-2008 

Expiration Date: 06-03-2009 

Activity Code: DP1 

Summary: Purpose. The NIDA Avant-Garde Award Program for HIV/AIDS Research is meant to complement NIDAs traditional investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose high-impact research that will open new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative open new areas of research or lead to new avenues of treatment and prevention for HIV/AIDS among drug abusers.The proposed research should reflect ideas substantially different from those already being pursued by the investigator or others. The research proposed must be in an area described in the Trans NIH Plan for HIV-Related Research (http://www.oar.nih.gov/strategicplan/fy2009/). The 2009 Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-09-044. Pre-applications will be evaluated by a group of external reviewers.Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2009 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2009 Avant-Garde Awards were solicited under PAR-09-044. Funds Available and Anticipated Number of Awards. Approximately $2 million per year for 5 years has been set aside to fund 2-3 awards in 2009. Budget and Project Period. Awards will be for up to $500,000 in direct costs each year for five years, plus standard F&A costs, which will be determined at the time of award. Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply. Eligible Project Directors/Principal Investigators (PDs/PIs). Only investigators who submitted a pre-application (X02) in response to PAR-09-xxx and who were notified of the opportunity to submit full (DP1) applications are eligible to apply under this FOA. Recipients of the Avant-Garde Award (DP1) are required to commit the major portion (at least 51%) of their research effort to activities supported by the Avant-Garde Award. There are no citizenship or residency requirements. Number of PDs/PIs. Only one PD/PI (i.e., no multiple PDs/PIs) may be designated on the application. Number of Applications. Applicants may submit only one application as a PD/PI in response to this FOA. There is no limit to the number of applications that an institution may submit. Resubmissions. Resubmission applications are not allowed. All applications must be submitted as new regardless of any previous submissions to the Program. Renewals. Renewal applications are not permitted in response to this FOA. Special Date(s). This FOA uses non-standard due dates. See Receipt, Review and Anticipated Start Dates.  

2009 NIH Directors New Innovator Award Program (DP2) - RFA-RM-09-003

Organization: Roadmap 

Posting Date: 10-27-2008 

Expiration Date: 05-28-2009 

Activity Code: DP2 

Summary: -Purpose. The NIH Directors New Innovator (DP2) Award program was created in 2007 to support a small number of new investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The New Innovator Awards complement ongoing efforts by NIH and its Institutes and Centers to fund new investigators through R01 grants, which continue to be the major sources of NIH support for new investigators. The competition for the New Innovator Award in fiscal year 2009 will proceed in two phases. The first phase is a pre-application phase in response to PAR-09-013. Pre-applications will be evaluated by a group of external reviewers, and those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA. The 2009 New Innovator Awardees will be selected from this group of applicants. -Mechanism of Support. This FOA will utilize the DP2 grant mechanism. Pre-applications for 2009 New Innovator Awards were solicited under PAR-09-013. Applicants should read both FOAs. -Funds Available and Anticipated Number of Awards. Total funding available is approximately $55.7 million for the five-year period. It is anticipated that up to 24 awards will be made in 2009.  

2009 NIH Directors Pioneer Award Program (DP1) - RFA-RM-09-001

Organization: Roadmap 

Posting Date: 10-27-2008 

Expiration Date: 05-16-2009 

Activity Code: DP1 

Summary: Purpose. The NIH Directors Pioneer Award Program complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transformative approaches to addressing major biomedical or behavioral challenges. To be considered pioneering, the proposed research must reflect ideas substantially different from those already being pursued in the investigators laboratory or elsewhere. The NIH Directors Pioneer Award Program is a High-Risk Research initiative of the NIH Roadmap for Medical Research. The 2009 Pioneer Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-09-012. Pre-applications will be evaluated by a group of external reviewers, and those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA. The 2009 Pioneer awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2009 Pioneer Awards were solicited under PAR-09-012.Applicants must read both FOAs. Funds Available and Anticipated Number of Awards. Total funding available is approximately $5 million for the five-year period.It is anticipated that at least 5-10 awards will be made in 2009. 

2010 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1) - RFA-DA-10-012

Organization: NIDA 

Posting Date: 12-18-2009 

Expiration Date: 06-03-2010 

Activity Code: DP1 

Summary: Purpose. The NIDA Avant-Garde Award Program for HIV/AIDS Research is meant to complement NIDAs traditional investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose high-impact research that will open new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative open new areas of research or lead to new avenues of treatment and prevention for HIV/AIDS among drug abusers.The proposed research should reflect ideas substantially different from those already being pursued by the investigator or others. The research proposed must be in an area described in the Trans NIH Plan for HIV-Related Research (http://www.oar.nih.gov/strategicplan/fy2010/index.asp). The 2010 Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-068. Pre-applications will be evaluated by a group of external reviewers.Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2010 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the the DP1 grant mechanism. Pre-applications for 2010 Avant-Garde Awards were solicited under PAR-10-068. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIDA intends to commit approximately $2 million for 2-3 awards in fiscal year 2010. 

2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1) - RFA-DA-10-013

Organization: NIDA 

Posting Date: 01-26-2010 

Expiration Date: 07-03-2010 

Activity Code: DP1 

Summary: Purpose The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2010 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-095. Pre-applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2010 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2010 Translational Avant-Garde Awards were encouraged under PAR-10-095. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIDA intends to commit $2 million for 2-3 awards in fiscal 2010.  

2010 NIH Directors New Innovator Award Program (DP2) - RFA-RM-09-011

Organization: Roadmap 

Posting Date: 08-26-2009 

Expiration Date: 10-28-2009 

Activity Code: DP2 

Summary: Purpose. The NIH Directors New Innovator (DP2) Award program was created in 2007 to support a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The New Innovator Awards complement ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage. The NIH Directors New Innovator Award Program is a High-Risk Research initiative of Research Teams of the Future. Mechanism of Support. This FOA will utilize the DP2 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $80 million in response to this FOA in fiscal year 2010. We anticipate that at least 33 awards will be made in fiscal year 2010.  

2010 NIH Directors Pioneer Award Program (DP1) - RFA-RM-09-010

Organization: Roadmap 

Posting Date: 08-18-2009 

Expiration Date: 10-21-2009 

Activity Code: DP1 

Summary: Purpose. The NIH Directors Pioneer Award Program complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges. To be considered pioneering, the proposed research must reflect ideas substantially different from those already being pursued in the investigators laboratory or elsewhere. Awardees must commit the major portion (at least 51%) of their research effort to activities supported by the Pioneer Award. The NIH Directors Pioneer Award Program is a High-Risk Research initiative of Research Teams of the Future. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit approximately $6 million for at least 7 awards in fiscal year 2010.  

2011 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1) - RFA-DA-11-002

Organization: NIDA 

Posting Date: 09-23-2010 

Expiration Date: 05-27-2011 

Activity Code: DP1 

Summary: Purpose. The NIDA Avant-Garde Award Program for HIV/AIDS Research is meant to complement NIDAs traditional investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose high-impact research that will open new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative open new areas of research or lead to new avenues of treatment and prevention for HIV/AIDS among drug abusers. The proposed research should reflect ideas substantially different from those already being pursued by the investigator or others. The research proposed must be in an area described in the Trans NIH Plan for HIV-Related Research http://www.oar.nih.gov/strategicplan/fy2011/index.asp. The 2011 Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-10-287. Pre-applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA (DP1). The 2011 Avant-Garde awardees will be selected from this group of applicants. Mechanism of Support. This FOA will utilize the DP1 grant mechanism. Pre-applications for 2011 Avant-Garde Awards were solicited under PAR-10-287. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIDA intends to commit approximately $2 million for 2-3 awards in fiscal year 2011.  

2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1) - RFA-DA-11-009

Organization: NIDA 

Posting Date: 02-03-2011 

Expiration Date: 06-28-2011 

Activity Code: DP1 

Summary: The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2011 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-11-102. Applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified by April 26 of the opportunity to submit full applications under this FOA (DP1). The 2011 Avant-Garde awardees will be selected from this group of applicants.  

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top